Qube Research & Technologies (QRT)
ALXO icon

Qube Research & Technologies (QRT)’s ALX Oncology ALXO Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$216K Buy
+107,647
New +$205K ﹤0.01% 2937
2025
Q4 		– Sell
-16,946
Closed -$31K – 3649
2025
Q3 		$31K Sell
16,946
-27,187
-62% -$23.5K ﹤0.01% 3244
2025
Q2 		$18.3K Sell
44,133
-102,844
-70% -$51.9K ﹤0.01% 3263
2025
Q1 		$91.6K Buy
146,977
+8,507
+6% +$10.2K ﹤0.01% 3015
2024
Q4 		$231K Sell
138,470
-319,247
-70% -$491K ﹤0.01% 2797
2024
Q3 		$833K Buy
457,717
+457,146
+80,061% +$1.7M ﹤0.01% 2094
2024
Q2 		$3.44K Buy
+571
New +$7.02K ﹤0.01% 3107
2022
Q4 		– Sell
-19,686
Closed -$188K – 2432
2022
Q3 		$188K Sell
19,686
-66,412
-77% -$774K ﹤0.01% 1794
2022
Q2 		$697K Buy
+86,098
New +$938K 0.01% 1276
2022
Q1 		– Sell
-19,190
Closed -$412K – 2410
2021
Q4 		$412K Buy
+19,190
New +$828K ﹤0.01% 1650

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ALXO Position: Q1 2026 in Review

Qube Research & Technologies (QRT) opened a new position in ALX Oncology (ALXO) in Q1 2026: 107,647 shares worth $216K. The stake represents ﹤0.01% of the portfolio and ranks #2937 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in ALXO as recently as Q3 2025.

Qube Research & Technologies (QRT) first reported a position in ALXO in Q4 2021 and has held it in 10 quarters since. The position peaked at $833K in Q3 2024. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Qube Research & Technologies (QRT) held 107,647 shares of ALX Oncology worth $216K as of Q1 2026.
  • ALX Oncology was a new Qube Research & Technologies (QRT) position in Q1 2026.
  • ALX Oncology made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #2937 holding.
  • Qube Research & Technologies (QRT) first reported a position in ALX Oncology in Q4 2021 and has held it in 10 quarters since.
  • Qube Research & Technologies (QRT)'s ALX Oncology position peaked at $833K in Q3 2024.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.